Advertisement
APVO vs NCEL
Which Stock Would AI Choose? Aptevo Therapeutics (APVO) vs. NewcelX (NCEL) Stock Comparison
Key Takeaways
- Aptevo Therapeutics (APVO) is a clinical-stage immuno-oncology company advancing its lead blood-cancer candidate, mipletamig, in frontline acute myeloid leukemia (AML).
- NewcelX (NCEL) is a clinical-stage regenerative medicine company developing stem-cell-derived therapies for Type 1 diabetes, ALS, and other neurological disorders.
- Both are pre-revenue, micro-cap biotechnology names, making them high-risk, catalyst-driven equities rather than cash-flow or valuation stories.
- APVO has reported repeated positive efficacy readouts and secured analyst Buy ratings in recent months, while NCEL remains earlier in its clinical pipeline, still working toward an Investigational New Drug (IND) filing for its lead program.
- Tickeron AI Verdict: Aptevo Therapeutics (APVO) — the AI currently favors APVO based on more advanced clinical data, more consistent positive catalysts, and firmer relative positioning.
- For more context, explore APVO Major News and APVO Today's Price Move, as well as NCEL Major News and NCEL Today's Price Move.
- To see which trading strategies are best suited to current market conditions, explore Trending AI Robots.
Introduction
Investors scanning the small- and micro-cap biotechnology space frequently weigh high-upside, high-risk names against one another. Aptevo Therapeutics (APVO) and NewcelX (NCEL) both sit at the pre-revenue, clinical-stage end of the healthcare sector, yet they pursue very different scientific paths — immuno-oncology versus regenerative cell therapy. This stock comparison examines their business models, recent price behavior, catalysts, and market positioning. It is most relevant for traders and investors comfortable with elevated volatility and binary clinical outcomes, where a single data readout or financing event can meaningfully reshape share prices. Neither company is a diversified or established enterprise, so relative performance here hinges on pipeline progress, cash runway, and sentiment rather than earnings or revenue growth.
APVO Overview and Recent Performance
APVO, or Aptevo Therapeutics, is a clinical-stage biotechnology company headquartered in Seattle that develops bispecific and multispecific antibody immunotherapies for cancer using its ADAPTIR and ADAPTIR-FLEX platforms. Its lead candidate, mipletamig, is being evaluated in frontline acute myeloid leukemia (AML), a difficult-to-treat blood cancer. In recent weeks, the company has highlighted encouraging clinical results — including a reported 93% clinical benefit rate in evaluable TP53-mutated patients and data showing a meaningful share of frontline AML patients advancing to potentially curative stem-cell transplant. These readouts have underpinned bullish analyst commentary, including Buy recommendations from firms such as Citigroup and Roth Capital. Aptevo has also moved to strengthen its balance sheet, securing a $60 million equity line of credit to extend its funding runway. On the other hand, the shares have experienced substantial volatility and a historically wide trading range, and a 1-for-18 reverse stock split completed in late 2025 reflects the dilution and low-price pressures common to early-stage biotechs. The stock trades near the lower end of its 52-week range, with a micro-cap market capitalization, underscoring both its speculative profile and its sensitivity to clinical and financing news.
NCEL Overview and Recent Performance
NCEL, or NewcelX Ltd., is a clinical-stage regenerative medicine company headquartered in Zurich, Switzerland, formed through the late-2025 merger of NLS Pharmaceutics and Kadimastem. The company is developing stem-cell-derived cell therapies and related programs, with its lead asset, NCEL-101, targeting a functional cure for Type 1 diabetes by combining stem-cell-derived islets with immune protection. Its pipeline also includes AstroRx for amyotrophic lateral sclerosis (ALS) and the DOXA platform for narcolepsy and other central nervous system disorders. In recent months, NewcelX has announced a successful Type B pre-IND (pre-Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) for NCEL-101, expanded its global intellectual property portfolio with a Brazilian patent grant, and completed small private placements priced at a premium to market. These developments signal progress but remain early-stage relative to APVO's clinical data. NewcelX is pre-revenue with a modest market capitalization and limited cash, and it continues to rely on periodic equity financings. The shares have shown periodic momentum tied to pipeline milestones, but the company's valuation is driven almost entirely by forward-looking clinical and regulatory potential rather than current financial results.
Trending AI Robots
For traders seeking a more systematic approach to names like these, Tickeron's Trending AI Robots page curates a focused selection of AI trading bots from a much larger library of hundreds of automated strategies that collectively trade thousands of different tickers. Because market conditions shift constantly, only the strategies best aligned with the current environment earn a place in this curated section. Each bot operates with its own trading style, timeframe, performance history, statistics, and basket of tickers, allowing users to compare approaches rather than rely on a single signal. Exploring the available bots — with their documented win rates, trade counts, and performance metrics — can help investors evaluate how systematic, rules-based strategies are positioning across volatile micro-cap biotech names and the broader market.
Head-to-Head Comparison
Although both companies are clinical-stage biotechs, their risk profiles and growth drivers diverge sharply. Aptevo Therapeutics operates in immuno-oncology, where its mipletamig program is already generating human efficacy and safety data in a Phase 1b/2 setting — a level of clinical validation NewcelX has not yet reached for its lead asset. NewcelX, by contrast, is positioned in regenerative medicine and cell therapy, a field with high scientific promise but longer timelines and greater manufacturing complexity; its NCEL-101 program is still progressing through IND-enabling work toward a first clinical trial. From a catalyst standpoint, APVO has produced a steady cadence of data readouts and analyst actions in recent weeks, while NCEL's news flow has centered on regulatory meetings, patents, and financing. Risk factors also differ: APVO faces dilution and reverse-split-related volatility, while NCEL faces earlier-stage development risk and a thinner cash position. Market sentiment currently appears more responsive to APVO's tangible clinical results than to NCEL's longer-dated milestones, though both stocks remain highly sensitive to headline-driven moves.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would currently favor APVO over NCEL. Aptevo offers more advanced clinical validation, a more consistent stream of positive data catalysts, and firmer analyst support, all of which tend to produce more durable trend characteristics in systematic models. NewcelX's stem-cell platform holds considerable long-term potential, but its lead program is at an earlier stage, and its momentum is more dependent on milestone announcements that are further out. The relative positioning, therefore, tilts toward APVO on the strength of nearer-term, data-driven catalysts. This assessment reflects a probabilistic, trend- and catalyst-based comparison rather than a definitive forecast, and both names carry substantial binary risk given their pre-revenue status.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APVO is a Hold and NCEL is a Hold.
APVO sees MACD Histogram just turned negative
APVO saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 06, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 44 instances where the indicator turned negative. In 41 of the 44 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where APVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for APVO entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +2.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where APVO advanced for three days, in 141 of 186 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
APVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.366) is normal, around the industry mean (3.498). P/E Ratio (0.003) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. APVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
NCEL's Stochastic Oscillator is sitting in overbought zone for 1 day
Expect a price pull-back in the near future.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 50-day moving average for NCEL moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NCEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
NCEL broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NCEL entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NCEL's RSI Oscillator exited the oversold zone, 33 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on NCEL as a result. In 77 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for NCEL just turned positive on November 03, 2026. Looking at past instances where NCEL's MACD turned positive, the stock continued to rise in 31 of 38 cases over the following month. The odds of a continued upward trend are 82%.
Following a +11.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where NCEL advanced for three days, in 186 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. NCEL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.640) is normal, around the industry mean (3.498). P/E Ratio (4.929) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NCEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
APVO | ||
|---|---|---|
OUTLOOK RATING 1..100 | 79 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 52 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 95 | |
P/E GROWTH RATING 1..100 | 97 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| APVO | NCEL | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 85% | 2 days ago 90% |
| Stochastic ODDS (%) | N/A | 2 days ago 90% |
| Momentum ODDS (%) | N/A | 2 days ago 88% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 82% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 84% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Advances ODDS (%) | 8 days ago 76% | 22 days ago 84% |
| Declines ODDS (%) | 2 days ago 90% | 3 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 84% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
APVO’s FA Score shows that 0 FA rating(s) are green while NCEL’s FA Score has 0 green FA rating(s).
- APVO’s FA Score: 0 green, 5 red.
- NCEL’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
APVO’s TA Score shows that 3 TA indicator(s) are bullish while NCEL’s TA Score has 4 bullish TA indicator(s).
- APVO’s TA Score: 3 bullish, 3 bearish.
- NCEL’s TA Score: 4 bullish, 5 bearish.
Price Growth
APVO (@Biotechnology) experienced а -20.59% price change this week, while NCEL (@Biotechnology) price change was +8.33% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
APVO is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
NCEL and
Correlation & Price change
A.I.dvisor indicates that over the last year, NCEL has been loosely correlated with APVO. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if NCEL jumps, then APVO could also see price increases.
| Ticker / NAME | Correlation To NCEL | 1D Price Change % | ||
|---|---|---|---|---|
| NCEL | 100% | +4.00% | ||
| APVO - NCEL | 63% Loosely correlated | -4.42% | ||
| CANF - NCEL | 62% Loosely correlated | -1.19% | ||
| MLEC - NCEL | 58% Loosely correlated | N/A | ||
| IRON - NCEL | 54% Loosely correlated | +4.16% | ||
| RANI - NCEL | 46% Loosely correlated | -2.47% | ||
More | ||||